Her condition was refractory to standard-dose insulin infusion and deteriorated owing to renal failure.14) Habeb et al. reported a 71-year-old man with metastatic prostate cancer who developed DKA six months after starting capivasertib. The gene discussed is INS; the disease is metastatic prostate carcinoma.